Zhou X, Shen X, Johnson JS, Spakowicz DJ, Agnello M, Zhou W, et al. Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease. bioRxiv: the preprint server for biology. United States; 2024. p. 2024.02.01.577565.

Visconti A, Le Roy CI, Rosa F, Rossi N, Martin TC, Mohney RP, et al. Interplay between the human gut microbiome and host metabolism. Nat Commun. 2019;10(1):4505.

Article  PubMed  PubMed Central  Google Scholar 

Albillos A, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72(3):558–77.

Article  CAS  PubMed  Google Scholar 

Budden KF, Gellatly SL, Wood DLA, Cooper MA, Morrison M, Hugenholtz P, et al. Emerging pathogenic links between microbiota and the gut–lung axis. Nat Rev Microbiol. 2017;15(1):55–63.

Article  CAS  PubMed  Google Scholar 

Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The central nervous system and the gut microbiome. Cell. 2016;167(4):915–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang T, Cheng J, Hu Y. Gut microbiota as a promising therapeutic target for age-related sarcopenia. Ageing Res Rev. 2022;81:101739.

Article  CAS  PubMed  Google Scholar 

Schreiber F, Balas I, Robinson MJ, Bakdash G. Border control: the role of the microbiome in regulating epithelial barrier function. Cells. 2024;13(6).

Arrieta MC, Stiemsma LT, Amenyogbe N, Brown EM, Finlay B. The intestinal microbiome in early life: health and disease. Front Immunol. 2014. https://doi.org/10.3389/fimmu.2014.00427.

Article  PubMed  PubMed Central  Google Scholar 

Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–14.

Article  PubMed  Google Scholar 

Su GL, Ko CW, Bercik P, Falck-Ytter Y, Sultan S, Weizman AV, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology. 2020;159(2):697–705.

Article  CAS  PubMed  Google Scholar 

Zhao Y, Dong BR, Hao Q. Probiotics for preventing acute upper respiratory tract infections. Cochrane Acute Respiratory Infections Group, editor. Cochrane Database Syst Rev. 2022. https://doi.org/10.1002/14651858.CD006895.pub4.

Article  PubMed  PubMed Central  Google Scholar 

AlFaleh K, Anabrees J, Bassler D, Al-Kharfi T. Cochrane review: probiotics for prevention of necrotizing enterocolitis in preterm infants. Evid-Based Child Health. 2012;7(6):1807–54.

Article  Google Scholar 

Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165(9):609–16.

Article  PubMed  PubMed Central  Google Scholar 

U.S. Food and Drug Administration (FDA). Fecal microbiota products [Internet]. 2023. Available from: https://www.fda.gov/vaccines-blood-biologics/fecal-microbiota-products.

Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing clostridium difficile infection. JAMA. 2014;312(17):1772–8.

Article  CAS  PubMed  Google Scholar 

Dubberke ER, Lee C, Orenstein R, Khanna S, Hecht G, Fraiz J. Efficacy and safety of RBX2660 for the prevention of recurrent Clostridium difficile infection: results of the PUNCH CD 2 trial. Open Forum Infect Dis. 2016;3(suppl_1):1341.

Article  Google Scholar 

Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, et al. SER-109, an oral microbiome therapy for recurrent clostridioides difficile infection. N Engl J Med. 2022;386(3):220–9.

Article  CAS  PubMed  Google Scholar 

Khanna S, Sims M, Louie TJ, Fischer M, LaPlante K, Allegretti J, et al. SER-109: an oral investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infection (rCDI). Antibiotics. 2022;11(9):1234.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louie T, Golan Y, Khanna S, Bobilev D, Erpelding N, Fratazzi C, et al. VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA. 2023;329(16):1356–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malard F, Loschi M, Huynh A, Cluzeau T, Guenounou S, Legrand F, et al. Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial. EClinicalMedicine. 2023;62: 102111.

Article  PubMed  PubMed Central  Google Scholar 

Liu NN, Jiao N, Tan JC, Wang Z, Wu D, Wang AJ, et al. Multi-kingdom microbiota analyses identify bacterial–fungal interactions and biomarkers of colorectal cancer across cohorts. Nat Microbiol. 2022;7(2):238–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kazemian N, Ramezankhani M, Sehgal A, Khalid FM, Kalkhoran AHZ, Narayan A, et al. The trans-kingdom battle between donor and recipient gut microbiome influences fecal microbiota transplantation outcome. Sci Rep. 2020;10(1):18349.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol. 2017;2(5):1–6.

Article  Google Scholar 

Cani PD, Depommier C, Derrien M, Everard A, de Vos WM. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nat Rev Gastroenterol Hepatol. 2022;19(10):625–37.

Article  PubMed  Google Scholar 

Cani PD, de Vos WM. Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol. 2017;8:1765.

Article  PubMed  PubMed Central  Google Scholar 

Wortelboer K, Koopen AM, Herrema H, de Vos WM, Nieuwdorp M, Kemper EM. From fecal microbiota transplantation toward next-generation beneficial microbes: the case of Anaerobutyricum soehngenii. Front Med (Lausanne). 2022;9:1077275.

Article  PubMed  PubMed Central  Google Scholar 

Requena T, Solo de Zaldívar B, Peláez C, Martínez-Cuesta MC. Chapter 4—dietary influence on human microbiome. In: Goel G, Requena T, Bansal S, editors. Human-gut microbiome [Internet]. Academic Press; 2022. p. 59–80. Available from: https://www.sciencedirect.com/science/article/pii/B9780323913133000076.

Belzer C, Chia LW, Aalvink S, Chamlagain B, Piironen V, Knol J, et al. Microbial metabolic networks at the mucus layer lead to diet-independent butyrate and vitamin B(12) production by intestinal symbionts. mBio. 2017;8(5).

Shahi SK, Freedman SN, Murra AC, Zarei K, Sompallae R, Gibson-Corley KN, et al. Prevotella histicola, a human gut commensal, is as potent as COPAXONE® in an animal model of multiple sclerosis. Front Immunol. 2019. https://doi.org/10.3389/fimmu.2019.00462.

Article  PubMed  PubMed Central  Google Scholar 

Balakrishnan B, Luckey D, Bodhke R, Chen J, Marietta E, Jeraldo P, et al. Prevotella histicola protects from arthritis by expansion of allobaculum and augmenting butyrate production in humanized mice. Front Immunol. 2021. https://doi.org/10.3389/fimmu.2021.609644.

Article  PubMed  PubMed Central  Google Scholar 

Itano A, Maslin D, Ramani K, Mehraei G, Carpenter N, Cormack T, et al. Clinical translation of anti-inflammatory effects of Prevotella histicola in Th1, Th2, and Th17 inflammation. Front Med. 2023. https://doi.org/10.3389/fmed.2023.1070433.

Article  Google Scholar 

Evelo Biosciences, Inc. A long-term extension trial in participants with atopic dermatitis who participated in previous EDP1815 trials [Internet]. Bethesda: National Library of Medicine (US); 2023. Report No.: NCT05439941. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05439941.

Shkoporov AN, Turkington CJ, Hill C. Mutualistic interplay between bacteriophages and bacteria in the human gut. Nat Rev Microbiol. 2022;20(12):737–49.

Article  CAS  PubMed  Google Scholar 

Raeisi H, Noori M, Azimirad M, Mohebbi SR, Asadzadeh Aghdaei H, Yadegar A, et al. Emerging applications of phage therapy and fecal virome transplantation for treatment of Clostridioides difficile infection: challenges and perspectives. Gut Pathog. 2023;15(1):21.

Article